Peripheral neuropathy due to therapy with paclitaxel, gemcitabine and cisplatin in patients with advanced ovarian cancer

Journal of Neuro-Oncology

Volumn 63, Issue 2, 2003, Pages 201-205

  Verstappen, C C P ^a   Postma, T J ^a   Hoekman, K ^a   Heimans, J J ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Cisplatin; Gemcitabine; Paclitaxel and peripheral neuropathy

Indexed keywords

CARBOPLATIN; CIMETIDINE; CISPLATIN; CLEMASTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GAIT DISORDER; GRIP STRENGTH; HUMAN; MOTOR DYSFUNCTION; NEUROLOGIC EXAMINATION; NEUROPATHY; NEUROTOXICITY; OVARY CANCER; PARESTHESIA; PERCEPTIVE THRESHOLD; PERIPHERAL NEUROPATHY; QUANTITATIVE ANALYSIS; RECURRENT CANCER; SENSORY NEUROPATHY; VIBRATION DISEASE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUROLOGIC EXAMINATION; OVARIAN NEOPLASMS; PACLITAXEL; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 0038040711     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023952106955     Document Type: Article

References (25)

1. Neijt JP, Allen DG, Colombo N: Carcinoma of the ovary. In: Peckham M, Pinedo HB, Veronesi U (eds), Oxford Text Book of Oncology 1995, pp 1293-1307
2. Trope C, Kaern J, Kristensen G, Rosenberg P, Sorbe B: Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer. Ann Oncol 8: 803-806, 1997
3. Mayerhofer K, Kucera E, Zeisler H, Speiser P, Reinthaller A, Sevelda P: Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy. Gynecol Oncol 64: 109-113, 1997
4. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the anti-tumor activity of gemcitabine (difluoro-2-deoxycytidine). Cancer Res 50: 4417-4420, 1990
5. Catimel G, Vermorken JB, Clavel M, De Mulder P, Judson I, Sessa C, Piccart M, Bruntsch U, Verweij J, Wanders J et al.: A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 543-547, 1994
6. Lund B, Hansen OP, Neijt JP, Theilade K, Hansen M: Phase II study of gemcitabine (2′,2′-difluorodeoxycytydine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994
7. Shapiro JD, Millward MJ, Rischin D, Michael M, Walcher V, Francis PA, Toner GC: Activity of gemcitabine in patients with advanced ovarian cancer: Responses seen following platinum and paclitaxel. Gynecol Oncol 63: 89-93, 1996
8. Bergman AM, Ruiz Van Haperen VWT, Veerman G, Kuiper CM, Peters GJ: Synergistic interaction between gemcitabine and cisplatin in vitro. Clin Cancer Res 2:521-530, 1996
9. Peters GJ, Ruiz Van Haperen VWT, Bergman AM, Veerman G, Smitskamp-Wilms E, Van Moorsel CJ, Kuiper CM, Braakhuis BJ: Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 23 (Suppl. 10): 16-24, 1996
10. Van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ: Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice. Eur J Cancer 35: 808-814, 1999
11. Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M: Cisplatin-gemcitabine combination in advanced non-small cell lung cancer (NSCLC). A phase II study. J Clin Oncol 15: 297-303, 1997
12. Krakowski I, Delpomme D, Beaduin M et al.: Gemcitabine (GEM) in combination with cisplatin (CP) in stage III or IV ovarian cancer: Preliminary phase II results. Proc ASCO 16: 16: 65a (Abstract 1300), 1997
13. Nogue M, Cirera L, Arcusa M, Batiste-Alentorn E, Balil A, Font A, Perez-Gracia JL, Carrasco EM, Tusquets I: Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer. Anticancer Drugs 13: 389-845, 2002
14. Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J: Paclitaxel delivered as a 3-h infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity. Gynecol Oncol 62: 166-168, 1996
15. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Comblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020, 1993
16. Green MR: Gemcitabine safety overview. Semin Oncol 23(Suppl. 10): 32-35, 1996
17. Dormann AJ, Grünwald T, Wigginghaus B, Huchzermeyer H: Gemcitabine-associated autonomic neuropathy. The Lancet 351: 644, 1998
18. Postma TJ, Vermorken JB, Liefting AJM, Pinedo HM, Heimans JJ: Paclitaxel-induced neuropathy. Ann Oncol 6: 489-494, 1995
19. Postma TJ, Hoekman K, Van Riel JMGH, Heimans JJ, Vermorken JB: Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neuro-Oncol 45: 241-246, 1999
20. Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, De Cataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G: Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: A phase I-II study. J Clin Oncol 17: 2316-2325, 1999
21. Siegal T, Haim N: Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndrome, and muscle cramps. Cancer 66: 1117-1123, 1990
22. Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Redmind D, Gadia M, Stewart DJ: Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphological evidence of toxicity. J Clin Oncol 10: 795-803, 1992
23. Cavaletti G, Bogliun G, Marzorati L, Zincone A, Marzola M, Colombo N, Tredici G: Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75: 1141-1150, 1995
24. Iniguez C, Larrode P, Mayordomo JI, Gonzales P, Adelantado S, Yubero A, Tres A, Morales F: Reversible peripheral neuropathy induced by single administration of high-dose paclitaxel. Neurology 51: 868-700, 1998
25. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997